Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metaprolol tartrate tablet formulations

AAPS PharmSciTech

Volumn 1, Issue 2, 2000, Pages

  Eddington, Natalie D ^a   Rekhi, Guvinder Singh ^b   Lesko, Larry J ^c   Augsburger, Larry L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Elan Pharmaceutical Research Corporation   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Bioavailability; Dissolution; Metoprolol; Propranolol; Scale up

Indexed keywords

METOPROLOL TARTRATE; PROPRANOLOL; METOPROLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BATCH PROCESS; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; PH; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SCALE UP; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; TIME; BIOAVAILABILITY; BLOOD; CHEMISTRY; DELAYED RELEASE FORMULATION; DIET RESTRICTION; METABOLISM; METHODOLOGY; PHARMACOKINETICS; SOLUBILITY; STANDARD; TABLET;

ADULT; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; FASTING; FEMALE; HUMANS; MALE; METOPROLOL; PROPRANOLOL; SOLUBILITY; TABLETS; THERAPEUTIC EQUIVALENCY; WEIGHTS AND MEASURES;

EID: 1342331488     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1007/BF02830524     Document Type: Article

References (8)

1. Skelly JP, Van Burskirk GA, Savello DR, et al. Workshop report, scale-up of immediate release oral solid dosage forms. Pharm Res. 1993;10:313-316.
2. Immediate Release Solid Oral Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing and Controls: In Vitro Dissolution Testing; In Vivo Bioequivalence Documentation Guidance. Fed. Reg. 60, 61638-61643, November 30, 1995.
3. Amidon GJ, Lennernas H, Shah VP, Crimson JR. A theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
4. Augsburger LL, Shangraw R, Lesko LJ, Williams R. An approach toward establishing a scientific foundation for interpreting regulations and workshop reports on scale-up and post approval changes. Pharm Res. 1994;11: S-143.
5. Eddington ND, Ashraf M, Augsburger LL, et al. Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets. Pharm Dev Tech. 1998;3:535-547.
6. Rekhi GS, Eddington ND, Fossler MJ, Schwartz P, Lesko LJ, Augsburger LL. Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate release tablet formulations. Pharm Dev Tech. 1997;29:11-24.
7. USP XXIII chapter <1088>, United States Pharmacopeial Convention, Inc.; Rockville, Maryland, pp1927-1929.
8. Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on dissolution profiles. Pharm Tech. 1996;6:64-74.